Dalantercept, a recombinant fusion protein designed to target the activin receptor-like kinase 1 (ALK1) receptor, was evaluated in a Phase II clinical trial that comprised 28 patients with endometrial cancer. This evidence concerns the gene ACVRL1 and endometrial cancer.